Evaluate the Efficacy of Armodafinil for Patients With B-cell Lymphoma and Severe Fatigue

Inclusion Criteria for both arms:

* Age ≥ 18 with diagnosis of B-cell lymphoma
* Average score of ≥ 7 on daily worst fatigue severity assessment from the BFI questionnaire during screening
* Able to demonstrate appropriate use of the wrist actigraphy device and to complete questionnaires
* ECOG performance status 0-2
* Laboratory values:
* Hemoglobin ≥ 10 g/dL
* Total Bilirubin ≤ 1.5 x institutional ULN
* AST/ALT ≤ 2.5 x institutional ULN
* Creatinine ≤ 1.5 x institutional ULN
* Albumin ≥ 3.5 g/dl
* Life expectancy \> 6 months
* IRB-approved informed consent form must be signed before any protocol-specific screening procedures are performed.

Inclusion criteria for patients undergoing R-CHOP chemotherapy:

* Scheduled to receive 6 cycles of standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy as first-line treatment

Inclusion criteria for patients in remission following chemotherapy and/or radiotherapy:

* May have received one prior regimen of chemotherapy and/or radiotherapy
* Adequate response to upfront chemotherapy and/or radiotherapy
* Indolent lymphomas - must have achieved a partial or complete response with no immediate plans for further treatment
* Aggressive lymphomas - must have achieved a complete response:

  * ≥ 4 weeks since completion of chemotherapy
  * ≥ 8 weeks since completion of radiotherapy
  * ≤ 18 months since completion of chemotherapy or radiotherapy

Exclusion Criteria for both arms:

* Uncontrolled medical and/or psychiatric condition that may cause fatigue or that the PI feels is clinically significant and might adversely affect patient safety (such as sleep disorders, moderate/severe depression, metabolic/endocrine abnormalities, infections)
* History of clinically significant cardiac disorders, such as left ventricular hypertrophy or mitral valve prolapse experienced in conjunction with receiving CNS stimulants
* History of serious skin reactions, such as serious rash or Stevens-Johnson Syndrome
* Concurrent stimulant medication
* Any other active malignancy within the past 3 years except cervical carcinoma in situ and non-melanoma skin cancers
* Known CNS involvement by lymphoma
* Cachexia
* Use of opioids at time of randomization
* Known sensitivity to modafinil and/or armodafinil